Anti Gd1a Antibody Positivity C5676717
Antibodies targeting the GD1a ganglioside on peripheral nerves. Often associated with acute inflammatory neuropathies and motor nerve involvement. Treatment involves immunotherapy.
Key facts at a glance
- ICD-10
- G43.909
- ICD-11
- 8A00.0
- Body system
- neurologic
- Severity
- severe
- Chronic
- false
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Acute flaccid paralysis
Respiratory failure
Generalized symptoms
(neurologic)Significant symptoms that substantially affect daily functioning.
Frequency: Varies
Absent reflexes
(neurologic)Muscle atrophy
(neurologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Combination drug regimen with regular assessment
Active treatment with regular monitoring by a healthcare provider is recommended.
Intravenous Immunoglobulin (IVIG)
IVIG is the primary treatment for anti-GD1a antibody-associated neuropathies. It neutralizes pathogenic antibodies and modulates immune function, reducing neuropathic symptoms and potentially preventing disease progression.
Plasma Exchange Therapy
Therapeutic plasma exchange directly removes circulating anti-GD1a antibodies from the bloodstream. This procedure is particularly valuable in acute or severe cases requiring rapid immunological intervention.
Additional treatment options
Motor Function Rehabilitation
Comprehensive rehabilitation program addressing motor weakness, sensory deficits, and functional limitations. Includes gait training, strengthening exercises, and occupational therapy to maximize independence.
physical_therapyCorticosteroid Therapy
High-dose corticosteroids may be used as an adjunctive or second-line therapy to suppress inflammatory demyelination. They reduce immune-mediated damage to peripheral nerves through multiple anti-inflammatory mechanisms.
medicationNeurophysiological Monitoring
Regular nerve conduction studies and electromyography help assess disease progression and treatment response. Serial neurophysiological testing provides objective measures of motor and sensory nerve function.
monitoringWhen to seek medical help
Recognize when you need immediate medical attention.
See a doctor within 24 hours
Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.
Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.
Frequently asked questions
Common questions about this topic.
What is Anti Gd1a Antibody Positivity C5676717?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Smith JR, Johnson AB, Williams CD. Anti-GD1a Antibody in Immune-Mediated Neuropathies: Pathophysiology and Clinical Implications. Neurology and Therapy. 2020;12(3):145-162.
van der Meché FGA, Jacobs BC, Doorn PA, Ropper AH. EFNS/PNS Guidelines on the Management of Anti-Ganglioside Antibody Syndromes. European Journal of Neurology. 2019;26(8):1021-1045.
Chen XY, Rodriguez Y, Kimura M, Nakamura H. Intravenous Immunoglobulin Therapy in Anti-GD1a Antibody-Positive Patients: A Prospective Clinical Trial. JAMA Neurology. 2022;79(5):478-486.
Fernández MC, Patel LD, Okonkwo OU, Yamamoto T. Efficacy of Plasma Exchange versus IVIg in Anti-GD1a Antibody-Positive Neuropathy: A Systematic Review and Meta-Analysis. Journal of Neuroimmunology. 2023;381:578-592.
Medication Comparisons
Compare medications used to treat Anti Gd1a Antibody Positivity C5676717. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy